A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

As new SARS-CoV-2 variants continue to emerge and impact communities worldwide, next-generation vaccines that enhance protective mucosal immunity may have a significant impact on productive infection and transmission. We have developed recombinant non-replicating adenovirus serotype 5 (rAd5) vaccine...

Full description

Bibliographic Details
Main Authors: Sarah N. Tedjakusuma, Colin A. Lester, Elena D. Neuhaus, Emery G. Dora, Samanta Gutierrez, Molly R. Braun, Sean N. Tucker, Becca A. Flitter
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Vaccines
Subjects:
adenovirus vaccines
immunity
mucosal
SARS-CoV-2
immunoglobulin A
Online Access:https://www.mdpi.com/2076-393X/12/2/132

Similar Items

Similar Items